- About Us
- Studies for Risk Management
- Consulting on Risk Management
- Other Research Services
- Study Recruitment
The Drug Safety Research Unit (DSRU) is an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.
In partnership with doctors in England, the DSRU, led by Director Professor Saad Shakir, aims to protect patients in primary and specialist care from unwanted adverse effects of newly marketed medicines using our unique methods of monitoring patients during the lifecycle of medicines.
Dr Alison Evans, study manager for the ROSE ACS study (Rivaroxaban Observational Safety Evaluation post Acute Coronary Syndrome), is delighted to announce that the first patients have been recruited to the study on the same day the study went live! The non-interventional post-authorisation study is examining the safety and utilisation of rivaroxaban when used as part of normal clinical practice for the secondary prevention of atherothrombotic events in adults after acute coronary syndrome (ACS). The study uses the DSRU’s Specialist Cohort Event Monitoring (SCEM) methodology and is supported by a team of regional study facilitators, with assistance from the NIHR Cardiovascular Speciality Group. The study team is currently seeking Trusts which would like to participate in the study. Further information about the ROSE ACS study can be found here. To access the website for investigator registration and patient registration please click here or visit http://hub.dsru.org